ARCHIVES

Most Comprehensive Centers Score High; Few May Be In Trouble; Directors Back Program

This article is from The Cancer Letter archive.

Vol. 04 No. 20 | May 19, 1978

Download PDF Visit The Full Archive

Related Articles

Adherez Issued U.S. Patent for Catenin Molecule Inhibition.

July 4, 2003

Pathology Review Confirms Reserpine As Carcinogen

March 14, 1980

Two NCI Officials Leave for Industry, Academia: Carl Barrett Goes to Novartis, Karen Antman Named Provost and Dean at Boston University.

February 18, 2005

Clearinghouse Finds Five Compounds Pose Risk To Humans

March 2, 1979

Nader Group Backs FDA In controversy Over Drug Testing

February 11, 1977

The shadow of Iressa lingered over the FDA Oncologic Drugs Advisory Committee as the panel voted down Genasense (Genta Inc.) and RSR13 (Allos Therapeutics Inc.) at its May 3 meeting. If anyone thought the bar had been lowered for drug approvals, they were mistaken.

May 7, 2004